Not provided
Not provided
Not provided
Not provided
slow recruitment
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Vancomycin is an essential antimicrobial which is frequently used in the ICU for suspected methicillin-resistant Staphylococcus aureus (MRSA) infection. Therefore, it is vital to optimize the dosing of vancomycin for this critically ill population. The most efficacious method of administering vancomycin is debated in the literature. Since vancomycin is associated with slow bactericidal activity, it is important to closely monitor serum concentrations so as to achieve early target serum concentration, particularly when treating aggressive S. aureus infections. One study has shown that vancomycin infused continuously may enable faster and more consistent achievement of a therapeutic serum concentration when compared to intermittent infusion. A faster achievement in the goal serum vancomycin concentration would be a protective factor for intensive care unit mortality in patients with MRSA infection.
Currently in the surgical ICU (SICU) of our institute, vancomycin is administered based on a vancomycin dosing nomogram. Less than fifty percent of the ICU patients following this nomogram achieved target vancomycin concentration of 15 after 24 hours. To better achieve target vancomycin concentration in 24 hours, we developed a new vancomycin dosing nomogram with a continuous infusion. The aim is to determine which of the two dosing nomogram is more efficient and safer for SICU patients.
Early administration of effective antibiotics is the cornerstone of management in septic patients; however, altered pharmacokinetics in critically ill patients has lead to subtherapeutic antibiotic exposure with standard antibiotic dosing and administration. This is further evidenced by low therapeutic target achievement with our intermittent vancomycin dosing nomogram. Administering vancomycin by continuous infusions may lead to achieving a therapeutic concentration and AUC24 more quickly than the administration by intermittent infusions as well as provide a more consistent concentration throughout the dosing period. Therefore, a new vancomycin continuous infusion nomogram was developed to increase the achievement of a goal vancomycin concentration within 24 hours.
We hypothesized that vancomycin administered as continuous infusion would achieve the therapeutic target sooner and more consistently than when administered as an intermittent infusion in critically ill surgical patients. The aims of this study were to determine the dosing differences between continuous (CIV) and intermittent (IIV) dosing in critically ill surgical intensive care unit (SICU) patients with preserved renal function and whether calculated Cockcroft-Gault Creatinine Clearance (CG CrCL) or measured creatinine clearance (CrCL) is a better predictor of vancomycin clearance.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Vancomycin with continuous infusion | Experimental | 24 hours continuous infusion |
|
| Vancomycin with intermittent dose interval | Active Comparator | infusion rate 1000mg/hr |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Vancomycin continuous infusion | Drug | Vancomycin 24 hour intravenous continuous infusion |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants Who Achieved the Target Vancomycin Concentration | The therapeutic level was defined as 15-20 mcg/mL for IIV and 15-25 mcg/mL for CIV | 24 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Time Required to Reach the Therapeutic Levels | The therapeutic level was defined as 15-20 mcg/mL for IIV and 15-25 mcg/mL for CIV | as long as participants are receiving Vancomycin (mean (SD) 9 (3.8) days for continuous, 8.4 (4.1) days for intermittent) |
| Vancomycin Concentration at 24 Hours |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Hsin Lin, PharmD | Massachusetts General Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| MGH | Boston | Massachusetts | 02116 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Vancomycin With Continuous Infusion | continuous 24 hours intravenous infusion Vancomycin continuous infusion: Vancomycin 24 hour intravenous continuous infusion |
| FG001 | Vancomycin With Intermittent Dose Interval |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Vancomycin intermittent dosing interval | Drug | Vancomycin intravenous infusion at rate 1000mg/hr |
|
The therapeutic level was defined as 15-20 mcg/mL for IIV and 15-25 mcg/mL for CIV |
| 24 hours |
infusion rate 1000mg/hr
Vancomycin intermittent dosing interval: Vancomycin intravenous infusion at rate 1000mg/hr
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Vancomycin Continous Infusion | Vancomycin continuous infusion: Vancomycin 24 hour intravenous continuous infusion infusion rate 1000mg/hr |
| BG001 | Intermittent Infusion | infusion rate 1000mg/hr Vancomycin intermittent dosing interval: Vancomycin intravenous infusion at rate 1000mg/hr |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Region of Enrollment | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants Who Achieved the Target Vancomycin Concentration | The therapeutic level was defined as 15-20 mcg/mL for IIV and 15-25 mcg/mL for CIV | Posted | Count of Participants | Participants | 24 hours |
|
|
| ||||||||||||||||||||||||||||||
| Secondary | Time Required to Reach the Therapeutic Levels | The therapeutic level was defined as 15-20 mcg/mL for IIV and 15-25 mcg/mL for CIV | Posted | Mean | Standard Deviation | hours | as long as participants are receiving Vancomycin (mean (SD) 9 (3.8) days for continuous, 8.4 (4.1) days for intermittent) |
|
| ||||||||||||||||||||||||||||||
| Secondary | Vancomycin Concentration at 24 Hours | The therapeutic level was defined as 15-20 mcg/mL for IIV and 15-25 mcg/mL for CIV | Posted | Mean | Standard Deviation | mcg/mL | 24 hours |
|
|
Adverse event data were collected while subjects are receiving vancomycin therapy.
Nephrotoxicity was defined as an increase in serum creatinine (SCr) by 0.5 mg/dL or at least a 50% increase from baseline over 2 consecutive SCr values.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Vancomycin Continous Infusion | continuous 24 hours intravenous infusion Vancomycin continuous infusion: Vancomycin 24 hour intravenous continuous infusion | 0 | 22 | 1 | 22 | ||
| EG001 | Intermittent Infusion | infusion rate 1000mg/hr Vancomycin intermittent dosing interval: Vancomycin intravenous infusion at rate 1000mg/hr | 0 | 22 | 4 | 22 |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Nephrotoxicity | Renal and urinary disorders | Systematic Assessment | Nephrotoxicity was defined as an increase in serum creatinine (SCr) by 0.5 mg/dL or at least a 50% increase from baseline over 2 consecutive SCr values. |
|
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Hsin Lin | Massachusetts General Hospital | 6177241314 | hlin13@mgh.harvard.edu |
| Male |
|
|
|